Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

After the identification of discrete relapse-risk categories in patients with acute promyelocytic
leukemia (APL) receiving all-trans retinoic and idarubicin (AIDA)–like therapies, the Gruppo …

Purpose The initial results of the APL0406 trial showed that the combination of all-trans-retinoic
acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and …

Background Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1
protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from …

The main objective of this study was to investigate whether patients with chronic myeloid
leukemia (CML) in treatment with long-term therapy imatinib have a different health-related …

Nilotinib has a higher binding affinity and selectivity for BCR-ABL with respect to imatinib
and is an effective treatment of chronic myeloid leukemia (CML) after imatinib failure. In a …

The anti-CD33 antibody calicheamicinconjugate gemtuzumab ozogamicin (GO) was used
to treat 16 patients with acute promyelocytic leukemia (APL) who had relapsed at the …

Purpose The definition of disease-specific prognostic scores plays a fundamental role in the
treatment decision-making process in myelodysplastic syndrome (MDS), a group of myeloid …

The aim of this study was to describe the presenting features, the frequency and outcome of
myeloid sarcoma (MS) diagnosed in our Institution from January 1995 to December 2000. …

Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis
reportedly has been poor. The authors investigated whether disease characteristics before the …